The study should evaluate distribution of 99mTc- ADAPT6 in patients with primary HER2-positive and HER2-negative breast cancer. The primary objective are: 1. To assess distribution of 99mTc- ADAPT6 in normal tissues and in tumours over time; 2. To assess kinetics of 99mTc- ADAPT6 in blood; 3. To evaluate dosimetry of 99mTc- ADAPT6; 4. To obtain initial information concerning safety and tolerability of 99mTc- ADAPT6 after single intravenous injection: The secondary objective is: 1.To compare the tumour imaging data with the concerning HER2 expression obtained by immunohistochemistry (IHC) or fluorescent in situ hybridisation (FISH) analysis of biopsy samples:
Age range
18 Years – 80 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Gamma camera-based whole-body 99mTc-ADAPT6 uptake value (%)
Timeframe: 6 hours
SPECT-based 99mTc-ADAPT6 uptake value in tumor lesions (kcounts)
Timeframe: 6 hours
SPECT-based 99mTc-ADAPT6 background uptake value (kcounts)
Timeframe: 6 hours
Tumor-to-background ratio (SPECT)
Timeframe: 6 hours